The Clinical Spectrum of New-Onset Status Epilepticus

被引:9
|
作者
Chakraborty, Tia [1 ]
Hocker, Sara [1 ]
机构
[1] Mayo Clin, Dept Neurol, Rochester, MN USA
关键词
epilepsy; neurology; new-onset refractory status epilepticus; seizures; status epilepticus; INDEPENDENT EXTERNAL VALIDATION; REFRACTORY STATUS EPILEPTICUS; 1ST EPISODE; MORTALITY; EPIDEMIOLOGY; PROGNOSIS; ADULTS; STESS; SCORE;
D O I
10.1097/CCM.0000000000003776
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: There is a paucity of data on patients with new-onset status epilepticus in patients without a prior history of epilepsy; we aimed to describe clinical characteristics and assess variables predictive of outcomes. Design: Retrospective cohort. Setting: Quaternary academic medical center. Patients: Adult patients with new-onset status epilepticus. Methods: Retrospective review of adults with new-onset status epilepticus admitted to Mayo Clinic, Rochester MN between January 1, 1990, and December 31, 2015, was performed. Patient demographics, status epilepticus etiology, Status Epilepticus Severity Score, and status epilepticus classification per the Status Epilepticus Severity Score were recorded. Six-month mortality and functional outcomes defined as modified Rankin scale (>= 3 at last follow-up was considered poor) were primary outcomes. Refractory status epilepticus was a secondary outcome. Interventions: None. Measurements and Main Results: One-hundred seventy-seven patients were included. Status epilepticus was convulsive in 124 (70.1%) and nonconvulsive in 53 (29.9%); 96 cases (54.2%) were refractory status epilepticus. Mean age at onset was 63 +/- 18 years; 52.5% were greater than or equal to 65 years. Etiologies were acute in 50.8%, progressive in 18.1%, remote in 19.2%, and unknown in 11.9% patients. Six-month mortality was 32.2%, and 70.1% had poor modified Rankin scale at mean follow-up 3.1 +/- 3.5 years. Age greater than or equal to 65 was a significant predictor of poor functional outcome and 6-month mortality. Loss of consciousness, status epilepticus classification, or age greater than or equal to 65 did not predict progression to refractory status epilepticus. Progression to refractory status epilepticus did not impact functional outcome or mortality at last follow-up. Conclusions: Poor outcomes in new-onset status epilepticus were associated with older age as well as predominantly progressive or remote symptomatic disease. Further prospective investigations assessing the course and outcomes of these patients would be useful in management and prognostication.
引用
收藏
页码:970 / 974
页数:5
相关论文
共 50 条
  • [1] New onset status epilepticus in older patients: Clinical characteristics and outcome
    Malter, M. P.
    Nass, R. D.
    Kaluschke, T.
    Fink, G. R.
    Burghaus, L.
    Dohmen, C.
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2017, 51 : 114 - 120
  • [2] The clinical analysis of new-onset status epilepticus
    Deng, Binlu
    Dai, Yuqian
    Wang, Qi
    Yang, Jie
    Chen, Xiang
    Liu, Ting-Ting
    Liu, Jie
    EPILEPSIA OPEN, 2022, 7 (04) : 771 - 780
  • [3] New-Onset Refractory Status Epilepticus with Claustrum Damage: Definition of the Clinical and Neuroimaging Features
    Meletti, Stefano
    Giovannini, Giada
    d'Orsi, Giuseppe
    Toran, Lisa
    Monti, Giulia
    Guha, Rahul
    Kiryttopoulos, Andreas
    Pascarella, Maria Grazia
    Martino, Tommaso
    Alexopoulos, Haris
    Spilioti, Martha
    Slonkova, Jana
    FRONTIERS IN NEUROLOGY, 2017, 8
  • [4] Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort)
    Sculier, Claudine
    Barcia Aguilar, Cristina
    Gaspard, Nicolas
    Gainza-Lein, Marina
    Sanchez Fernandez, Ivan
    Amengual-Gual, Marta
    Anderson, Anne
    Arya, Ravindra
    Burrows, Brian T.
    Brenton, James N.
    Carpenter, Jessica L.
    Chapman, Kevin E.
    Clark, Justice
    Gaillard, William D.
    Glauser, Tracy A.
    Goldstein, Joshua L.
    Goodkin, Howard P.
    Gorman, Mark
    Lai, Yi-Chen
    McDonough, Tiffani L.
    Mikati, Mohamad A.
    Nayak, Anuranjita
    Peariso, Katrina
    Riviello, James
    Rusie, Allison
    Sperberg, Katherine
    Stredny, Coral M.
    Tasker, Robert C.
    Tchapyjnikov, Dmitry
    Vasquez, Alejandra
    Wainwright, Mark S.
    Wilfong, Angus A.
    Williams, Korwyn
    Loddenkemper, Tobias
    EPILEPSIA, 2021, 62 (07) : 1629 - 1642
  • [5] New-Onset Status Epilepticus in Pediatric Patients: Causes, Characteristics, and Outcomes
    Jafarpour, Saba
    Hodgeman, Ryan M.
    Capeletto, Carolina De Marchi
    Avelar de Lima, Mateus Torres
    Kapur, Kush
    Tasker, Robert C.
    Loddenkemper, Tobias
    PEDIATRIC NEUROLOGY, 2018, 80 : 61 - 69
  • [6] New-onset status epilepticus and cluster seizures in the elderly
    Sinha, S.
    Satishchandra, P.
    Kalband, B. R.
    Thennarasu, K.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2013, 20 (03) : 423 - 428
  • [7] Clinical characteristics and treatment approach of established New-Onset status epilepticus (eNOSE): A Real-World multicenter experience
    Dono, Fedele
    Evangelista, Giacomo
    Rodorigo, Davide
    Rollo, Eleonora
    Romozzi, Marina
    Corniello, Clarissa
    Liviello, Davide
    Dasara, Michelangelo
    Capriati, Luca
    Quintieri, Paolo
    Servidei, Serenella
    Della Marca, Giacomo
    Calabresi, Paolo
    Sensi, Stefano L.
    Vollono, Catello
    EPILEPSY & BEHAVIOR, 2024, 159
  • [8] Response to anakinra in new-onset refractory status epilepticus: A clinical case
    Palacios-Mendoza, Michael
    Gomez, Ana
    Prieto, Julio
    Camilo Barrios, Juan
    Orera, Maria
    Massot-Tarrus, Andreu
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2022, 94 : 92 - 94
  • [9] New-onset refractory status epilepticus (NORSE)
    Mantoan Ritter, Laura
    Nashef, Lina
    PRACTICAL NEUROLOGY, 2021, 21 (02) : 119 - +
  • [10] Cytokines in new-onset refractory status epilepticus: ready for clinical use?
    Jin, Zhenghan
    Zhan, Yixin
    Chen, Shijia
    Zheng, Yang
    ACTA EPILEPTOLOGICA, 2024, 6 (01):